Bayer Yanks Trasylol from the Shelves
On the same day that the results of a long-awaited Canadian study on Trasylol were released, the drug’s maker, Bayer, announced it was pulling the anti-bleeding drug off the shelves.
Yesterday, the BART study was published in the New England Journal of Medicine. Researchers found that heart surgery patients who were given Trasylol were 53 percent more likely to die than patients who were given comparable and cheaper blood clotting drugs.
On May 14, Bayer notified the U.S. Food and Drug Administration that it will begin removing remaining Trasylol stock from the American market, most of which is in warehouses and in the possession of hospitals and physicians.
Bayer should have taken this step long ago.
The BART study is not the first to highlight the drug’s danger. Since 2006, three studies have linked Trasylol to an increased risk for kidney damage, stroke and death.
If Bayer had removed the drug from the market in 2006, it is estimated that 22,000 lives could have been saved.
Our firm currently represents several Trasylol victims and their families in lawsuits against Bayer. If you or a loved one suffered complications after taking Trasylol contact Carey & Danis. We can help. Carey & Danis is a national law firm that represents individuals injured by America's largest corporations.
For more information, fill out our online contact form or call Carey & Danis toll-free at 800-721-2519.
